| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
|
N Engl J Med
|
2009
|
12.07
|
|
2
|
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
|
N Engl J Med
|
2008
|
9.33
|
|
3
|
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
|
N Engl J Med
|
2014
|
9.25
|
|
4
|
Adult-to-adult transplantation of the right hepatic lobe from a living donor.
|
N Engl J Med
|
2002
|
6.64
|
|
5
|
Preliminary study of two antiviral agents for hepatitis C genotype 1.
|
N Engl J Med
|
2012
|
6.44
|
|
6
|
Response-guided telaprevir combination treatment for hepatitis C virus infection.
|
N Engl J Med
|
2011
|
6.31
|
|
7
|
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
|
Gastroenterology
|
2008
|
6.15
|
|
8
|
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
|
Gastroenterology
|
2004
|
4.27
|
|
9
|
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
|
Control Clin Trials
|
2004
|
3.46
|
|
10
|
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.
|
Clin Gastroenterol Hepatol
|
2010
|
2.96
|
|
11
|
Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features.
|
Arch Neurol
|
2004
|
2.71
|
|
12
|
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.
|
J Hepatol
|
2005
|
2.63
|
|
13
|
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
|
N Engl J Med
|
2014
|
2.54
|
|
14
|
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
|
Gastroenterology
|
2010
|
2.47
|
|
15
|
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
|
Hepatology
|
2008
|
2.44
|
|
16
|
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.
|
Gastrointest Endosc
|
2006
|
2.43
|
|
17
|
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
|
Hepatology
|
2011
|
2.01
|
|
18
|
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.
|
Hepatology
|
2005
|
1.93
|
|
19
|
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
|
Liver Transpl
|
2011
|
1.85
|
|
20
|
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.
|
Ann Surg
|
2004
|
1.79
|
|
21
|
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
|
Gastroenterology
|
2006
|
1.76
|
|
22
|
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|
Clin Gastroenterol Hepatol
|
2007
|
1.71
|
|
23
|
Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD.
|
Liver Transpl
|
2004
|
1.66
|
|
24
|
Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications.
|
Liver Transpl
|
2003
|
1.61
|
|
25
|
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.
|
Liver Transpl
|
2007
|
1.58
|
|
26
|
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.
|
Gastroenterology
|
2010
|
1.52
|
|
27
|
Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation.
|
Transplantation
|
2003
|
1.46
|
|
28
|
Long-term management after liver transplantation: primary care physician versus hepatologist.
|
Liver Transpl
|
2009
|
1.43
|
|
29
|
Review and management of drug interactions with boceprevir and telaprevir.
|
Hepatology
|
2012
|
1.42
|
|
30
|
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.
|
Gastroenterology
|
2009
|
1.35
|
|
31
|
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
|
Hepatology
|
2011
|
1.33
|
|
32
|
Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
|
Liver Transpl
|
2003
|
1.31
|
|
33
|
Drug-drug interactions during antiviral therapy for chronic hepatitis C.
|
Nat Rev Gastroenterol Hepatol
|
2013
|
1.19
|
|
34
|
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
|
Hepatology
|
2009
|
1.18
|
|
35
|
Management of the transplant recipient with chronic hepatitis C.
|
Clin Liver Dis
|
2013
|
1.15
|
|
36
|
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
|
Hepatology
|
2006
|
1.13
|
|
37
|
Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease.
|
Liver Int
|
2007
|
1.11
|
|
38
|
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.
|
Hepatology
|
2009
|
1.08
|
|
39
|
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
|
Hepatology
|
2008
|
1.03
|
|
40
|
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
|
Gastroenterology
|
2009
|
1.03
|
|
41
|
Model for end-stage liver disease (MELD) exception for polycystic liver disease.
|
Liver Transpl
|
2006
|
1.01
|
|
42
|
Atrial septal perforation from TIPS stent migration.
|
J Vasc Interv Radiol
|
2004
|
1.00
|
|
43
|
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
|
Clin Gastroenterol Hepatol
|
2008
|
0.98
|
|
44
|
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
|
Antivir Ther
|
2006
|
0.93
|
|
45
|
MELD: the answer or just more questions?
|
Gastroenterology
|
2003
|
0.93
|
|
46
|
Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.
|
Am J Gastroenterol
|
2006
|
0.93
|
|
47
|
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.
|
Hepatology
|
2008
|
0.91
|
|
48
|
Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation.
|
Am J Transplant
|
2004
|
0.90
|
|
49
|
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
|
Transplantation
|
2015
|
0.88
|
|
50
|
HCV NS5B polymerase inhibitors.
|
Clin Liver Dis
|
2009
|
0.88
|
|
51
|
Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation.
|
Liver Transpl
|
2003
|
0.88
|
|
52
|
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
|
Ann Intern Med
|
2015
|
0.87
|
|
53
|
Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavarin treatment for hepatitis C.
|
J Clin Gastroenterol
|
2004
|
0.87
|
|
54
|
Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection.
|
Liver Transpl
|
2003
|
0.85
|
|
55
|
The variable presentations and broadening geographic distribution of hepatic fascioliasis.
|
Clin Gastroenterol Hepatol
|
2012
|
0.84
|
|
56
|
Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.
|
Hepatology
|
2013
|
0.84
|
|
57
|
De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy.
|
Dig Dis Sci
|
2006
|
0.83
|
|
58
|
Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis.
|
Clin Gastroenterol Hepatol
|
2004
|
0.82
|
|
59
|
High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
|
Hepatology
|
2008
|
0.82
|
|
60
|
Hepatitis C virus: a critical appraisal of approaches to therapy.
|
Clin Gastroenterol Hepatol
|
2008
|
0.81
|
|
61
|
Controversies in the management of hepatitis C virus infection after liver transplantation.
|
Liver Transpl
|
2003
|
0.81
|
|
62
|
Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group.
|
Am J Transplant
|
2002
|
0.81
|
|
63
|
Cholecystokinin-cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel.
|
Clin Nucl Med
|
2012
|
0.80
|
|
64
|
Everolimus and mTOR inhibitors in liver transplantation: opening the "box".
|
Liver Transpl
|
2006
|
0.80
|
|
65
|
Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
|
Liver Transpl
|
2002
|
0.80
|
|
66
|
Hepatocellular carcinoma extension into the right atrium.
|
Liver Transpl
|
2003
|
0.79
|
|
67
|
The effects of desflurane and propofol on portosystemic pressure in patients with portal hypertension.
|
Anesth Analg
|
2003
|
0.78
|
|
68
|
Rapid, accurate, and sensitive fatty acid ethyl ester determination by gas chromatography-mass spectrometry.
|
J Lab Clin Med
|
2006
|
0.78
|
|
69
|
Cholecystokinin-cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel.
|
Clin Gastroenterol Hepatol
|
2011
|
0.78
|
|
70
|
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
|
Am J Gastroenterol
|
2012
|
0.78
|
|
71
|
Noninvasive assessment of liver function.
|
Curr Opin Gastroenterol
|
2015
|
0.78
|
|
72
|
Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C.
|
Antivir Ther
|
2006
|
0.77
|
|
73
|
Somatostatin, estrogen, and polycystic liver disease.
|
Gastroenterology
|
2013
|
0.75
|
|
74
|
Consensus Interferon for Recurrent Hepatitis C Infection in Nonresponders to Peginterferon and Ribavirin After Liver Transplant.
|
Exp Clin Transplant
|
2015
|
0.75
|
|
75
|
PRO view: treat to prevent recurrence of HCV.
|
Liver Int
|
2015
|
0.75
|